so are you going to tell us something or just shitpost?
Nuvectra
- Thread starter anonymous
- Start date
-
- Tags
- None
hey... you can't over promise and under deliver if you don't promise
Would someone please tell me the MRI Conditional ratings of all the neuromod companies. There seems to be conflation of the facts going on and its making it difficult to understand the advantages of one company's system over another. MDT clearly has the the most promising being the only 3T full body right? Jude is right behind them then BSC???
There's this wicked-awesome thing called a "search engine". You just type in a short description of what you want to know, "keywords" if you will, and it will return a listing of relevant websites. Amazingly enough, there's even a brief snippet of the content triggering the return of the listing. If the result looks promising, you just select the result, and you can read the details to learn more. With this marvel of modern technology, you access information in ways that were inconceivable to your forefathers and don't have to rely on a bunch of assholes who are more interested in talking how short someone is than do your homework for you.
The facts are simple. Nevro is the only company that the FDA calls clinically superior.
well.. that would only be one fact rather than facts.
as soon as you stop pretending there aren't trade offs and that there are advantages/disadvantages to other systems you'll be in a lot better shape and probably sell more devices.
probably sells for a company that cannot make MRI claims....
If MRI is so important, Medtronic should be the dominant player, no? They've had it the longest and also have the most comprehensive MRI compatible offering.
10Q report from Nuvectra's management. Why did it take 8 years to commercialize a sub-par SCS device? Scott Drees will be taken to the woodshed after this disaster seeing he still can't eloquently spell out what Algovita's differentiating features are vs his competitors SCS systems.
Strategic and Financial Overview
We are a neurostimulation medical device company formed in 2008 to design and develop our neurostimulation technology platform for use in multiple different indications. Since our inception, the majority of our resources have been spent designing and developing Algovita. SCS was chosen as the first sector of the neurostimulation market to pursue, as we believe that it is a high growth and established market, there is an established regulatory and reimbursement pathway, and we believe that there are significant unmet needs in the SCS market. We currently have four significant competitors in the United States who may be better capitalized and who offer similar SCS devices that are already established and accepted in the market. While the competitive landscape for SCS remains challenging and we may face barriers to market acceptance of our product, we believe Algovita has certain differentiating features from other existing SCS systems that offer our patients and customers a broad set of capabilities and treatment options. Our U.S. sales team, in conjunction with marketing, is in the process of communicating and demonstrating to potential customers the features, perceived benefits and capabilities of Algovita.
We have a history of significant net losses, and we expect to continue to incur net losses for the foreseeable future. We expect that future revenue growth will come largely from sales of Algovita in the United States market beginning in the second half of 2016.
Was the second half of 2016 a windfall for Nuvectra?
Strategic and Financial Overview
We are a neurostimulation medical device company formed in 2008 to design and develop our neurostimulation technology platform for use in multiple different indications. Since our inception, the majority of our resources have been spent designing and developing Algovita. SCS was chosen as the first sector of the neurostimulation market to pursue, as we believe that it is a high growth and established market, there is an established regulatory and reimbursement pathway, and we believe that there are significant unmet needs in the SCS market. We currently have four significant competitors in the United States who may be better capitalized and who offer similar SCS devices that are already established and accepted in the market. While the competitive landscape for SCS remains challenging and we may face barriers to market acceptance of our product, we believe Algovita has certain differentiating features from other existing SCS systems that offer our patients and customers a broad set of capabilities and treatment options. Our U.S. sales team, in conjunction with marketing, is in the process of communicating and demonstrating to potential customers the features, perceived benefits and capabilities of Algovita.
We have a history of significant net losses, and we expect to continue to incur net losses for the foreseeable future. We expect that future revenue growth will come largely from sales of Algovita in the United States market beginning in the second half of 2016.
Was the second half of 2016 a windfall for Nuvectra?
Then why the F did they call you?? A call from a recruiter does not constitute an offer or opportunity to jump. Be realistic dude!
MDT is a joke! Everybody has left and MRI doesnt mean squat if patients are not getting pain relief! MDT had a shitty launch program with MRI from the get go. Only smart reps that launched it their way did well. Overall, doctors did and dont give a rats rear about MRI. Pain relief associated with outcomes is foremost. If you dont know the industry just look at how many MDT pain reps have left. Non existing leadership, class 1 recall on synchromed II PUMP that kills patients, and a NEVRO sales force composed of pissed off ex MdT reps. Flipping bizz like flipping burgers! Giving to MDT and flipping them the bird. Shitty RestoreSensor that sells fucken dreams and no solutions.
If Nuvectra is the the thing right now, why are we not seeing it in our facilities? Honestly, its just not out there. It can't be very appealing if it is not winning over customers, and thats the real testament to its effectiveness or appeal. Buying reps with guarantees, works for 12 months. Then reality sets in and after the guarantee runs its course, your back to zero customers but now, without any income
Meaning what? Nuvcrapa is in a crowded market and middle management is shady. Reps are running.
I dunno about you guys, but I really enjoyed taking docs out to strip clubs w Matty size 6 and then expensing it back to some schmuck fellow. You'll never catch a crack head. Nuvectra rules like O'Doyle.